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Introduction 
Methotrexate (MDC) in low doses has been commonly and effectively used in the treatment of
rheumatoid arthritis (RA)1,2. Such small weekly doses of the drug, in general, are considered to be safe
and non-toxic. However, when there is impairment of renal function or in patients having altered
metabolism due to infection or metabolic disease the cumulative effect of these small doses of MDC
can become life threatening3,4. We report a case of severe bone marrow suppression in a rheumatoid
arthritis patient on low dose MDC therapy.
Case Report 
In September 1992, a 52 years old woman with a history of bronchial asthma for 35 years, diabetes
mellitus for 3 years and RA for six years was prescribed MDC (oral, 10 mg/week) for her exacerbating
RA. Five months later she developed benign leiomyoblastoma, which was surgically removed. After
the operation, she was put back on low-dose oral MDC. However, she failed to show up in any of her
follow-up appointments and 10 weeks later was admitted with very high fever and gum bleeding. On
examination she was found to be pancytopenic (hemoglobin 7.6 gm/dl; white blood cells 0.9x109/1;
platelets 29x109/l), havingasevere infection of E. coli and a compromised renal function. She was
neutropenic (24% neutrophils; 69% lymphocytes; 7% eosinophils) and her chest X-ray revealed no
active disease in lungs. Her urinary pH of 5.5 may have been because of diabetic acidosis or severe
infection. Bacterial infection with E. coli was found resistant to ampicillin, amoxicillin and nalidixic
acid, but its sensitivity to amikacin facilitated management of this problem. For MDC toxicity, the
patient was given folinic acid 15 mg, 6 hourly for 4 days. Platelets were transfused repeatedly for her
thrombocytopenia. After 1 week of treatment, there was a significant improvement in her condition.
She became afrebrile and her neutropenia resolved to a great extent. WBC count increased to 3.
5x109/1 while neutrophils’ percentage rose to 44 (Table).
After another week of treatment (Table), the values of most hematologic and biochemical parameters
were within the normal range. Her neutropenia had completely resolved, but slight anemia which was
normocytic and normochromic still persisted. MDC levels in serum and erythrocytes were determined
using a sensitive radioassay5. Even a month after her last dose (10 mg) of MDC, the drug was detected
in serum (1.59 nM) as well as in erythrocytes (0.99 nM).
Discussion 
By a number of pharmacokinetic studies on MDC, it has been shown that more than 90% of the thug is
cleared within the first 24 hours after its administration6. With such a low dose (10 mg/week) of MDC,
there should hardly be any amount of drug detectable in plasma of the patient after 1 week post
ingestion. However, appreciable quantity (1.59 nM) of MDC was found in serum of the patient even 4
weeks after its ingestion. This suggests that her severe bone marrow suppression may have been
because of gradual accumulation of MDC in the body due to delayed plasma clearance of the drug.
This delayed clearance of MDC in the patient could have been mainly due to compromised renal
function (serum creatinine levels 2.3 mg/dl at the time of admission as shown in Table) and partly
because of her metabolically altered state due to diabetes mellitus. Although there is hardly any
information on the kinetics of MDC in diabetes patients, yet a number of studies have revealed that
alterations in the physiological environment of the body influence the biodisposition and fate of drugs7.
Moreover, MDC has been shown to precipitate In the acidic environment. Urinary pH, therefore, can
affect renal clearance of MTX8. The fact that the patient was a chronic diabetic and at the time of
admission had a urine pH of 5.5 suggests that she may have had an episode of diabetic aciduria which
resulted into precipitation of MDC in the kidneys leading to compromised renal function and further
decrease in the renal clearance of this drug. This impainnent of renal function with decreased renal
excretion of MDC could easily convert low- dose to intermediate-dose MDC therapy9. The
accumulation of MDC in the plasma could be the major cause of bone marrow suppression. It is not
clear whether severe bacterial infection was also the cause or the effect of neutropenia in this patient.
Hematopoietic toxicity following low-dose methotrexate therapy in RA patients has previously been
reported as well3,4,9. It has been estimated that 3-4% of the patients on MDC would experience
pancytopenia as its side effect10. In view of this case of bone marrow suppression following low dose
MDC therapy, it is suggested that those RA patients who have accompanying metabolic problems, such
as diabetes mellitus must be managed more carefully. There should be a regular follow-up of the
patients where they should be regularly monitored. According to the guidelines by the Health and
Public Policy Committee, American College of Physicians10, laboratory studies (total and differential
blood counts and platelet count, serum creatinine and liver enzymes) should be repeated every month.
MDC treatment is not recommended for an unreliable patient who is more likely to miss follow-up
appointments11 and utmost caution is needed when the patient, in addition to RA, has other metabolic
disorders, such as diabetes mellitus2.
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